Narjust Florez, Associate Director of Cancer Care Equity Program, Thoracic Medical Oncologist

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Astrazeneca
    Topic:
    targereted therapy
    Date added:
    11/16/2022
    Date updated:
    11/16/2022
    Relationship end date:
    11/20/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Pfizer
    Topic:
    Advisory board
    Date added:
    11/16/2022
    Date updated:
    11/16/2022
    Relationship end date:
    11/26/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    BMS
    Topic:
    Advisory board
    Date added:
    11/16/2022
    Date updated:
    11/16/2022
    Relationship end date:
    11/19/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    DSI
    Topic:
    Advisory board
    Date added:
    11/16/2022
    Date updated:
    11/16/2022
    Relationship end date:
    11/19/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Neogenomics
    Topic:
    Advisory board
    Date added:
    11/16/2022
    Date updated:
    11/16/2022
    Relationship end date:
    11/26/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Merck
    Topic:
    advisory board
    Date added:
    11/16/2022
    Date updated:
    11/16/2022
    Relationship end date:
    11/26/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    BMS
    Topic:
    CME content
    Date added:
    11/16/2022
    Date updated:
    11/16/2022
    Relationship end date:
    11/13/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Janssen
    Topic:
    CME content
    Date added:
    11/16/2022
    Date updated:
    11/16/2022
    Relationship end date:
    11/17/2025
Return to 2023 Summit on Cancer Health Disparities: Reframing and Addressing Barriers to Adoption of Precision Oncology